Showing 701-710 of 805 results for "".
- Lancer Skincare Launches At-Home Producthttps://practicaldermatology.com/news/20130117-lancer_skincare_launches_at-home_product/2459635/The Lancer Skincare collection now includes the Microcurrent Powerboost, a hand-held device to help tone, tighten, and correct imbalances in the skin. According to the company, the Microcurrent Powerboost allows daily skincare products to b
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and B
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also i
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota